Novo Nordisk suspended from industry body over serious breaches

Novo Nordisk, a Danish pharmaceutical firm, was suspended from the Association of the British Pharmaceutical Industry (ABPI) for two years due to “serious breaches” of the ABPI’s code of practice. Novo Nordisk reportedly failed to transparently disclose its sponsorship of a weight management course, which promoted its obesity drug Saxenda. A large scale Saxenda promotional campaign was disguised as a training course.